QQ客服 官方微博 反馈留言

	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
	Wei, Lai; Zhang, Mingxiang; Xu, Min; Chuang, Wan-Long; Lu, Wei; Xie, Wen; Jia, Zhansheng; Gong, Guozhong; Li, Yueqi; Bae, Si Hyun
刊名	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
	2016
卷号	31期号:[db:dc_citation_issue]页码:1860-1867
关键词	daclatasvir hepatitis C safety efficacy asunaprevir
ISSN号	0815-9319
DOI	[db:dc_identifier_doi]
URL标识	查看原文
WOS记录号	[DB:DC_IDENTIFIER_WOSID]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3231127
专题	西安交通大学
推荐引用方式 GB/T 7714	Wei, Lai,Zhang, Mingxiang,Xu, Min,et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2016,31([db:dc_citation_issue]):1860-1867.
APA	Wei, Lai.,Zhang, Mingxiang.,Xu, Min.,Chuang, Wan-Long.,Lu, Wei.,...&Mo, Ling.(2016).A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,31([db:dc_citation_issue]),1860-1867.
MLA	Wei, Lai,et al."A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin".JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31.[db:dc_citation_issue](2016):1860-1867.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。